- Home
- GOSS vs NCZ Comparison
GOSS vs NCZ Comparison
Compare GOSS & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NCZ
- Stock Information
- Founded
- GOSS 2015
- NCZ 2003
- Country
- GOSS United States
- NCZ United States
- Employees
- GOSS N/A
- NCZ N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- GOSS Health Care
- NCZ Finance
- Exchange
- GOSS Nasdaq
- NCZ Nasdaq
- Market Cap
- GOSS 262.5M
- NCZ 228.3M
- IPO Year
- GOSS 2019
- NCZ N/A
- Fundamental
- Price
- GOSS $1.40
- NCZ $12.23
- Analyst Decision
- GOSS Strong Buy
- NCZ
- Analyst Count
- GOSS 4
- NCZ 0
- Target Price
- GOSS $7.75
- NCZ N/A
- AVG Volume (30 Days)
- GOSS 1.3M
- NCZ 533.0K
- Earning Date
- GOSS 08-11-2025
- NCZ 01-01-0001
- Dividend Yield
- GOSS N/A
- NCZ 12.16%
- EPS Growth
- GOSS N/A
- NCZ N/A
- EPS
- GOSS N/A
- NCZ N/A
- Revenue
- GOSS $124,590,000.00
- NCZ N/A
- Revenue This Year
- GOSS N/A
- NCZ N/A
- Revenue Next Year
- GOSS $91.14
- NCZ N/A
- P/E Ratio
- GOSS N/A
- NCZ N/A
- Revenue Growth
- GOSS N/A
- NCZ N/A
- 52 Week Low
- GOSS $0.55
- NCZ $2.50
- 52 Week High
- GOSS $1.55
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- GOSS 57.95
- NCZ 53.59
- Support Level
- GOSS $1.22
- NCZ $12.15
- Resistance Level
- GOSS $1.36
- NCZ $12.48
- Average True Range (ATR)
- GOSS 0.08
- NCZ 0.13
- MACD
- GOSS -0.00
- NCZ -0.03
- Stochastic Oscillator
- GOSS 66.07
- NCZ 24.55
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.